

FDA approves new nail fungus treatment

June 12 2014



(HealthDay)—A new topical nail fungus treatment, Jublia, has been approved by the U.S. Food and Drug Administration.

Jublia (efinaconazole) is made by the Canadian company Valeant Pharmaceuticals International Inc., the *Associated Press* reported Wednesday.

Jublia comes in liquid form and is applied directly to the nail. According to Valeant, FDA approval was based on two studies involving more than 1,600 people with onychomycosis. The findings were published last year in the *Journal of the American Academy of Dermatology*. Cure rates were about 18 percent for the patients involved in one study, and about 15 percent for those involved in the other.

In a statement, Valeant said it plans to begin marketing Jublia late in 2014.

More information: [Health Highlights: June 11, 2014](#)

Copyright © 2014 [HealthDay](#). All rights reserved.

Citation: FDA approves new nail fungus treatment (2014, June 12) retrieved 25 April 2024 from <https://medicalxpress.com/news/2014-06-fda-fungus-treatment.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.